CYRAMZA

CYRAMZATM (Ramucirumab) in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.

CYRAMZATM (Ramucirumab) monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate

show more

CYRAMZATM (Ramucirumab) , in combination with docetaxel, is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy.

show more

For any queries and support, please contact us on below helpline:
1800 123 0021

Top